Clinical Trial

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Protocol Amendment History 1 change
notable Trial sites expanded: 49 -> 54 locations 2026-07-23
Trial Details
NCT Number NCT07441694
Lead Sponsor Incyte Corporation
Conditions Myeloproliferative Neoplasms
Enrollment 218 participants
Start Date 2026-05-11
Primary Completion 2030-05-24 (estimated)
Study Completion 2030-05-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-22